• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cohort selection in register-based studies of direct oral anticoagulant users with atrial fibrillation: An inevitable trade-off between selection bias and misclassification.

作者信息

Hellfritzsch Maja, Pottegård Anton, Haastrup Simone Bonde, Rasmussen Lotte, Grove Erik Lerkevang

机构信息

Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Basic Clin Pharmacol Toxicol. 2020 Jul;127(1):3-5. doi: 10.1111/bcpt.13423. Epub 2020 May 4.

DOI:10.1111/bcpt.13423
PMID:32364263
Abstract
摘要

相似文献

1
Cohort selection in register-based studies of direct oral anticoagulant users with atrial fibrillation: An inevitable trade-off between selection bias and misclassification.基于登记册的房颤直接口服抗凝剂使用者研究中的队列选择：选择偏倚与错误分类之间不可避免的权衡。
Basic Clin Pharmacol Toxicol. 2020 Jul;127(1):3-5. doi: 10.1111/bcpt.13423. Epub 2020 May 4.
2
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
3
[Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation].老年心房颤动患者的抗凝治疗
Kardiologiia. 2018 Oct(10):45-52.
4
Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy.意大利直接口服抗凝剂上市后早期，心房颤动患者预防卒中的抗凝治疗选择标准
Eur J Intern Med. 2017 Jun;41:e12-e14. doi: 10.1016/j.ejim.2017.04.016. Epub 2017 May 3.
5
Selection of Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动缺血性卒中患者口服抗凝剂的选择
J Stroke Cerebrovasc Dis. 2018 Oct;27(10):2627-2631. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.036. Epub 2018 Jun 30.
6
Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF.老年因素与老年心房颤动患者口服抗凝药物的应用：SAGE-AF。
J Am Geriatr Soc. 2020 Jan;68(1):147-154. doi: 10.1111/jgs.16178. Epub 2019 Oct 1.
7
Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study.非维生素 K 拮抗剂口服抗凝剂与华法林在心房颤动患者中的比较及与痴呆的关系：一项全国性倾向评分匹配队列研究。
J Am Heart Assoc. 2019 Jun 4;8(11):e011358. doi: 10.1161/JAHA.118.011358. Epub 2019 May 29.
8
Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation.口服抗凝药物处方趋势、患者特征、以及房颤患者用药依从性的决定因素。
Pharmacotherapy. 2020 Jan;40(1):40-54. doi: 10.1002/phar.2350. Epub 2019 Dec 17.
9
[Tactics of Selection of Anticoagulant Therapy in Patients With Atrial Fibrillation and Ischemic Heart Disease].[心房颤动合并缺血性心脏病患者抗凝治疗的选择策略]
Kardiologiia. 2018 Mar(3):43-52.
10
Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion.心房颤动患者电复律时直接口服抗凝剂的管理。
Medicina (Kaunas). 2019 Sep 30;55(10):660. doi: 10.3390/medicina55100660.

引用本文的文献

1
Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.使用非维生素K拮抗剂口服抗凝剂的心房颤动患者的药效学药物相互作用与出血结局：一项全国性队列研究
Cardiovasc Drugs Ther. 2025 Feb;39(1):133-143. doi: 10.1007/s10557-023-07521-5. Epub 2023 Nov 6.
2
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.华法林与非维生素 K 拮抗剂口服抗凝剂在房颤患者中的有效性和安全性。
Thromb Haemost. 2024 Feb;124(2):135-148. doi: 10.1055/s-0043-1769735. Epub 2023 Jun 27.
3
Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: A nationwide cohort study.
使用非维生素K拮抗剂口服抗凝剂的房颤合并跌倒史患者的临床结局：一项全国性队列研究。
Int J Cardiol Heart Vasc. 2023 May 18;47:101223. doi: 10.1016/j.ijcha.2023.101223. eCollection 2023 Aug.
4
Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study.衰弱对非维生素 K 拮抗剂口服抗凝剂（NOACs）在房颤患者中的疗效和安全性的影响：一项全国性队列研究。
Eur Heart J Qual Care Clin Outcomes. 2024 Jan 12;10(1):55-65. doi: 10.1093/ehjqcco/qcad019.
5
Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study.达比加群、利伐沙班、阿哌沙班和依度沙班用于房颤患者的长期比较疗效和安全性：一项全国性队列研究。
Front Pharmacol. 2023 Feb 2;14:1125576. doi: 10.3389/fphar.2023.1125576. eCollection 2023.
6
Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds.非维生素 K 拮抗剂口服抗凝药、质子泵抑制剂与胃肠道出血。
Heart. 2022 Apr;108(8):613-618. doi: 10.1136/heartjnl-2021-319332. Epub 2021 Aug 2.
7
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.在五个西欧国家，房颤患者对非维生素 K 拮抗剂口服抗凝剂治疗的坚持和依从性。
Europace. 2021 Nov 8;23(11):1722-1730. doi: 10.1093/europace/euab091.
8
Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants.抗凝药物暴露分类错误对直接口服抗凝药物出血风险的影响。
Br J Clin Pharmacol. 2021 Sep;87(9):3508-3517. doi: 10.1111/bcp.14764. Epub 2021 Mar 4.